Structural Characterization, Magnetic and Luminescent Properties of Praseodymium(III)‐4,4,4‐Trifluoro‐1‐(2‐Naphthyl)Butane‐1,3‐Dionato(1‐)Complexes

Four new Pr(III) mononuclear complexes of formula [Pr(ntfa)3(MeOH)2] (1), [Pr(ntfa)3(bipy)2] (2), [Pr(ntfa)3(4,4′-Mt2bipy)] (3) and [Pr(ntfa)3(5,5′-Me2bipy)] (4), where ntfa = 4,4,4-trifuoro-1-(naphthalen-2-yl)butane-1,3-dionato(1-), 5,5′-Me2bipy = 5,5′-dimethyl-2,2′-dipyridine, 4,4′-Mt2bipy = 4,4′-dimethoxy-2,2′-dipyridine, have been synthesized and structurally characterized. The complexes display the coordination numbers 8 for 1, 3 and 4, and 10 for 2. Magnetic measurements of complexes 1-4 were consistent with a magnetically uncoupled Pr3+ ion in the 3H4 ground state. The solid state luminescence studies showed that the ancillary chelating bipyridyl ligands in the 2-4 complexes greatly enhance the luminescence emission in the visible and NIR regions through efficient energy transfer from the ligands to the central Pr3+ ion; behaving as "antenna" ligands

Magnetic and Luminescence Properties of 8-Coordinated Pyridyl Adducts of Samarium(III) Complexes Containing 4,4,4-Trifluoro-1-(naphthalen-2-yl)-1,3-butanedionate

A novel series of polypyridyl adducts, [Sm(ntfa)3(NN)] (2-4), with ntfa = 4,4,4-trifluoro-1-(naphthalen-2-yl)-1,3-butanedionate, NN = 2,2′-bipyridine (bipy), 4,4′-dimethyl-2,2′-bipyridine (4,4′-Me2bipy), and 5,5′-dimethyl-2,2′-bipyridine (5,5′-Me2bipy) were synthesized from the precursor complex [Sm(ntfa)3(MeOH)2] (1) and the corresponding pyridyl ligands. Single X-ray crystallography showed that the complexes displayed 8-coordinated geometry. The solid pyridyl adducts 2-4 exhibited emission of luminescence in the NIR and visible regions with close quantum yields (QY = 0.20-0.25%). The magnetic data of 1-4 showed larger values than those expected for magnetically noncoupled Sm(III) complexes in the 6H5/2 ground state, with no saturation on the applied high magnetic field static at a temperature of 2 K

Magnetic and Luminescence Properties of 8-Coordinate Holmium(III) Complexes Containing 4,4,4-Trifluoro-1-Phenyl and 1-(Naphthalen-2-yl)-1,3-Butanedionates.

A new series of mononuclear Ho3+ complexes derived from the β-diketonate anions: 4,4,4-trifluoro-1-phenyl-1,3-butanedioneate (btfa−) and 4,4,4-trifuoro-1-(naphthalen-2-yl)-1,3-butanedionate (ntfa−) have been synthesized, [Ho(btfa)3(H2O)2] (1a), [Ho(ntfa)3(MeOH)2] (1b), (1), [Ho(btfa)3(phen)] (2), [Ho(btfa)3(bipy)] (3), [Ho(btfa)3(di-tbubipy)] (4), [Ho(ntfa)3(Me2bipy)] (5), and [Ho(ntfa)3(bipy)] (6), where phen is 1,10-phenantroline, bipy is 2,2′-bipyridyl, di-tbubipy is 4,4′-di-tert-butyl-2,2′-bipyridyl, and Me2bipy is 4,4′-dimethyl-2,2′-bipyridyl. These compounds have been characterized by elemental microanalysis and infrared spectroscopy as well as single-crystal X-ray difraction for 2-6. The central Ho3+ ions in these compounds display coordination number 8. The luminescence-emission properties of the pyridyl adducts 2-6 display a strong characteristic band in the visible region at 661 nm and a series of bands in the NIR region (excitation wavelengths (λex) of 367 nm for 2-4 and 380 nm for 5 and 6). The magnetic properties of the complexes revealed magnetically uncoupled Ho3+ compounds with no field-induced, single-molecule magnet (SMMs)

Diverse coordination numbers and geometries in pyridyl adducts of lanthanide(III) complexes based on beta-diketonate

t: Ten mononuclear rare earth complexes of formula [La(btfa)3 (H2O)2 ] (1), [La(btfa)3 (4,40 - Mt2bipy)] (2), [La(btfa)3 (4,40 -Me2bipy)2 ] (3), [La(btfa)3 (5,50 -Me2bipy)2 ] (4), [La(btfa)3 (terpy)] (5), [La(btfa)3 (phen)(EtOH)] (6), [La(btfa)3 (4,40 -Me2bipy)(EtOH)] (7), [La(btfa)3 (2-benzpy)(MeOH)] (8), [Tb(btfa)3 (4,40 -Me2bipy)] (9) and (Hpy)[Eu(btfa)4 ] (10), where btfa = 4,4,4-trifuoro-1-phenylbutane1,3-dionato anion, 4,40 -Mt2bipy = 4,40 -dimethoxy-2,20 -bipyridine, 4,40 -Me2bipy = 4,40 -dimethyl2,20 -bipyridine, 5,50 -Me2bipy = 5,50 -dimethyl-2,20 -bipyridine, terpy = 2,20 :60 ,20 -terpyridine, phen = 1,10-phenathroline, 2-benzpy = 2-(2-pyridyl)benzimidazole, Hpy = pyridiniumH+ cation) have been synthesized and structurally characterized. The complexes display coordination numbers (CN) eight for 1, 2, 9, 10, nine for 5, 6, 7, 8 and ten for 3 and 4. The solid-state luminescence spectra of Tb-9 and Eu-10 complexes showed the same characteristic bands predicted from the Tb(III) and Eu(III) ions. The Overall Quantum Yield measured (φTOT) at the excitation wavelength of 371 nm for both compounds yielded 1.04% for 9 and up to 34.56% for 10 years

Detection of blaCTX-M-15 in an integrative and conjugative element in four extensively drug-resistant Haemophilus parainfluenzae strains causing urethritis

Haemophilus parainfluenzae is a commensal organism with rising numbers of multidrug-resistant (MDR) strains. This pathogen is of increasing clinical relevance in urogenital infection. The aim of this work was to identify and characterise the molecular mechanisms of resistance associated with four cephalosporin-resistant H. parainfluenzae strains collected from patients with urethritis. Antimicrobial resistance was determined by microdilution following European Committee on Antimicrobial Susceptibility Testing cri-teria. Strains were then analysed by whole-genome sequencing to determine clonal relationship and the molecular basis of antimicrobial resistance. Finally, a phylogenetic analysis was performed on all urogen-ital MDR strains of H. parainfluenzae previously isolated in our hospital. All strains were resistant to ,B- lactams, macrolides, tetracycline, fluoroquinolones, chloramphenicol, cotrimoxazole, and aminoglycosides. The resistance profile was compatible with the presence of an extended-spectrum ,B-lactamase (ESBL). Whole-genome sequencing detected blaCTX-M-15 that conferred high minimum inhibitory concentrations to cephalosporins in two novel integrative and conjugative elements (ICEHpaHUB6 and ICEHpaHUB7) that also harboured a blaTEM-1 ,B-lactamase. This study shows a novel bla CTX-M-15 ESBL carried in an integrative conjugative element in four extensively drug-resistant H. parainfluenzae strains. This resistance determi-nant could be transmitted to other sexually transmitted pathogens and this is a cause for concern. (c) 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/

Insights into the Spin Dynamics of Mononuclear Cerium(III) Single-Molecule Magnets

Four novel CeIII mononuclear complexes of formulas [Ce(ntfa)3(MeOH)2] (1), [Ce(ntfa)3(5,5′-Me2bipy)] (2), [Ce(ntfa)3(terpy)] (3), and [Ce(ntfa)3(bipy)2] (4), where ntfa = 4,4,4-trifluoro-1-(naphthalen-2-yl)butane-1,3-dionato, 5,5′-Me2bipy = 5,5′-dimethyl-2,2′-dipyridyl, terpy = 2,2′:6′,2″-terpyridine, and bipy = 2,2′-bipyridine, have been synthesized and structurally characterized with CeIII displaying coordination numbers of 8, 8, 9, and 10, respectively. Magnetic measurements indicate that all the complexes show a field-induced single-ion magnet behavior under a small applied dc field. The magnetic analysis shows the relevance of the different spin relaxation mechanisms in the magnetic relaxation of the CeIII compounds, with special emphasis on the local-mode process. Multiconfigurational calculations were also performed to get more information on the axiality of the compounds

KITI (Estados Federados de Micronesia) (Ponapé) (Puerto). Cartas náuticas (1886). 1:8000

Escala gráfica de 10 cables o 1 milla [= 22,4 cm]. Coordenadas de la Isla Narmaur referidas posiblemente al meridiano de S. Fernando (E 164°20'24"/N6°47'00"). Orientado con lis en gráfico de declinación magnéticaOrografía por normalesIndica sondas batimétricas expresadas en metros, veriles, arrecifes y calidad de fondoNota indicando las características del puertoConsta el sello en seco de la Dirección de Hidrografí

Structural mapping in statistical word problems: A relational reasoning approach to Bayesian inference

Presenting natural frequencies facilitates Bayesian inferences relative to using percentages. Nevertheless, many people, including highly educated and skilled reasoners, still fail to provide Bayesian responses to these computationally simple problems. We show that the complexity of relational reasoning (e.g., the structural mapping between the presented and requested relations) can help explain the remaining difficulties. With a non-Bayesian inference that required identical arithmetic but afforded a more direct structural mapping, performance was universally high. Furthermore, reducing the relational demands of the task through questions that directed reasoners to use the presented statistics, as compared with questions that prompted the representation of a second, similar sample, also significantly improved reasoning. Distinct error patterns were also observed between these presented- and similar-sample scenarios, which suggested differences in relational-reasoning strategies. On the other hand, while higher numeracy was associated with better Bayesian reasoning, higher-numerate reasoners were not immune to the relational complexity of the task. Together, these findings validate the relational-reasoning view of Bayesian problem solving and highlight the importance of considering not only the presented task structure, but also the complexity of the structural alignment between the presented and requested relations

Efficacy of extended infusion of β-lactam antibiotics for the treatment of febrile neutropenia in haematologic patients : Protocol for a randomised, multicentre, open-label, superiority clinical trial (BEATLE)

Altres ajuts: The BEATLE study is a non-commercial, investigator-driven clinical trial funded by the Spanish Network for Research in Infectious Diseases (REIPI RD16/0016/0005; RD16/0016/0010) The Spanish Clinical Research Network (SCReN) provides clinical trial data monitoring and oversees pharmacovigilance (PT17/0017/0010).Background: Febrile neutropaenia (FN) is a very common complication in patients with haematological malignancies and is associated with considerable morbidity and mortality. Broad-spectrum antipseudomonal β-lactam antibiotics (BLA) are routinely used for the treatment of cancer patients with FN. However, the clinical efficacy of BLA may be diminished in these patients because they present with pathophysiological variations that compromise the pharmacokinetic (PK) parameters of these antibiotics. Optimised administration of BLA in prolonged infusions has demonstrated better clinical outcomes in critically ill patients. However, there is a paucity of data on the usefulness of this strategy in patients with FN. The aim of this study is to test the hypothesis that the administration of BLA would be clinically more effective by extended infusion (EI) than by intermittent infusion (II) in haematological patients with FN. Methods: A randomised, multicentre, open-label, superiority clinical trial will be performed. Patients with haematological malignancies undergoing chemotherapy or haematopoietic stem-cell transplant and who have FN and receive empirical antibiotic therapy with cefepime, piperacillin-tazobactam or meropenem will be randomised (1:1) to receive the antibiotic by EI (during half the time of the dosing interval) in the study group, or by II (30 min) in the control group. The primary endpoint will be clinical efficacy, defined as defervescence without modifying the antibiotic treatment administered within the first 5 days of therapy. The primary endpoint will be analysed in the intention-to-treat population. The secondary endpoints will be pharmacokinetic/pharmacodynamic (PK/PD) target achievement, bacteraemia clearance, decrease in C-reactive protein, overall (30-day) case-fatality rate, adverse events and development of a population PK model of the BLA studied. Discussion: Data on the usefulness of BLA administration in patients with FN are scant. Only three clinical studies addressing this issue have been published thus far, with contradictory results. Moreover, these studies had some methodological flaws that limit the interpretation of their findings. If this randomised, multicentre, phase IV, open-label, superiority clinical trial validates the hypothesis that the administration of BLA is clinically more effective by EI than by II in haematological patients with FN, then the daily routine management of these high-risk patients could be changed to improve their outcomes. Trial registration: European Clinical Trials Database: EudraCT 2018-001476-37. ClinicalTrials.gov, ID: NCT04233996